Protagonist raises $40m to test oral peptides in IBD
Protagonist Therapeutics raised $40m in Series C venture capital to take its first oral peptide drug candidate PTG-100 into clinical trials for the treatment of inflammatory bowel diseases (IBD).
Protagonist Therapeutics raised $40m in Series C venture capital to take its first oral peptide drug candidate PTG-100 into clinical trials for the treatment of inflammatory bowel diseases (IBD).